Obesity causes lifestyle-related metabolic disorders, including hypertension, dyslipidemia, and diabetes, which lead to advanced atherosclerosis or cardiovascular diseases. Chronic low-grade adipose tissue inflammation and insulin resistance are closely associated with the development of metabolic dysfunction ([@CIT0001]--[@CIT0003]). Lifestyle modifications are effective for the control of overweight and obesity; specifically, healthy dietary modifications and regular physical activity play key roles in preventing non-communicable diseases ([@CIT0004]).

Several dietary ingredients can substantially modulate overweight, obesity, obesity-related inflammation, obesity-related metabolic aberration, and cardiovascular risk ([@CIT0005]). The use of probiotics is one approach used to improve these abnormalities. Previous studies have reported that certain probiotic strains reduce visceral fat mass. This effect might reflect the fact that living beneficial bacteria produce short-chain fatty acids, including conjugated linoleic acid, within the gut tract ([@CIT0006]--[@CIT0008]). Probiotics modulate the gut microbiome by promoting competition among the constituents. These changes might cause a favorable environmental change, resulting in obesity suppression.

In a previous study, we screened bacterial strains belonging to 5 genera and 32 species, including 6 *Bifidobacterium* and 19 *Lactobacillus* species, for agonistic activities on peroxisome proliferator-activated receptor (PPAR) α and γ ([@CIT0009]). The results revealed that substances derived from *Lactobacillus amylovorus* CP1563 (CP1563) showed the highest dual agonistic activity for PPARα and γ *in vitro* among the strains screened. Feed-induced obese mice administered fragmented CP1563 showed reduced visceral fat mass and serum and liver triglyceride levels, and increased high-density lipoprotein (HDL) cholesterol. PPARα/γ are transcription factors that are primarily expressed in the liver, skeletal muscle, and white and brown adipose tissues, and these proteins are master regulators of lipid catabolism and homeostasis, glucose homeostasis, and lipid storage. PPARα regulates triglyceride-reducing steps and fatty acid oxidation. PPARα pharmacological agonists (fibrates) reduce the concentration of triglycerides and increase the serum concentration of HDL-cholesterol. PPARγ is highly expressed in adipocytes and regulates adipocyte differentiation, lipid storage, and glucose metabolism. Pharmacological PPARγ agonists (glitazones) improve insulin resistance and are widely used in the treatment of dyslipidemia. Dual-PPAR (PPARα/γ) pharmacological agonists (glitazars) exert positive effects on both lipid and glucose metabolism and have been recently developed as promising agents for the treatment of type 2 diabetes mellitus with dyslipidemia ([@CIT0010], [@CIT0011]). Anti-dyslipidemic and body fat--reducing effects were observed in fragmented CP1563-fed mice compared with mice-fed unprocessed bacterial cells ([@CIT0009]). The PPARα activation of fragmented CP1563 was also significantly higher than that of intact cells and was inversely correlated with the shredding size, that is, the length of the fragments. These observations suggested that the physical 'fragmentation' of bacteria is a key step in inducing the high agonistic activity of PPARα/γ. This process might expose the agonistic constituents of CP1563 cells.

In the present study, we examined the safety and efficacy of the oral administration of fragmented CP1563 on the depletion of body fat in a double-blinded, parallel group randomized clinical trial involving overweight and pre-obese subjects with a body mass index (BMI) ranging 25 or more but less than 30 kg/m^2^ ([@CIT0012], [@CIT0013]). Improvements in anthropometric measurements and markers were observed in obese class I subjects in the test group. This result suggests that the consumption of foods containing CP1563 reduces body fat and prevents metabolic syndrome.

Materials and methods {#S0002}
=====================

Preparation of CP1563 powder {#S0002-S20001}
----------------------------

*L. amylovorus* CP1563 was isolated from human fecal specimens and stocked in our culture collection library. It was screened as a strain with high potential by luciferase assays for PPAR ligand activity ([@CIT0009]). Here, the strain was cultured in an original food-grade medium ([Table 1](#T0001){ref-type="table"}) for 24 h at 37°C under a partially anaerobic atmosphere. At the start of the culture, the pH of the medium was adjusted to 6.8, and thereafter, the pH was controlled at 5.2 by the addition of sodium hydroxide. The resulting bacterial pellet was harvested by filtration with a ceramic filter, washed with sterilized water, and then filtered again. The washed bacterial pellet was then heat-inactivated and lyophilized. The resulting bacterial powder was fragmented by a FS-4 jet mill (Seishin Enterprise Co., Ltd., Tokyo, Japan) under the pressure of 0.64 MPa at a feed speed of 0.5 kg/h. The degree of fragmentation was evaluated as the ratio of the average long dimension of the fragmented bacterial cell preparation against that of the original bacterial cells. The quality of the fragmented bacterial preparation was checked by standard analysis methods ([Table 2](#T0002){ref-type="table"}).

###### 

Composition of the medium for CP1563 culture

  Ingredients                      Combination ratio (%)
  -------------------------------- -----------------------
  Glucose                          8.438
  Fish peptone                     3
  Yeast peptone                    4.5
  Yeast extract                    0.25
  Sodium acetate                   0.5
  Dipotassium hydrogen phosphate   0.445
  Magnesium sulfate                0.1
  Oleate glycerol ester            0.3
  Fermented barley lees            3.5
  Water                            78.97

The pH value of the medium was adjusted to 6.8 before sterilization, and after inoculation, the pH was controlled to approximately 5.2. All ingredients met the Japanese standards for food additives.

###### 

Results of general analysis of fragmented CP1563 powder

  Analytical items                Content          Detection limit   Analytical method
  ------------------------------- ---------------- ----------------- -------------------------------------------------
  Water                           3.3 g/100 g      --                Ambient-pressure heat method
  Protein                         81.9 g/100 g     --                Kjeldahl method
  Lipid                           5.8 g/100 g      --                Acid digestion method
  Ash                             5.9 g/100 g      --                Direct carburization method
  Carbohydrate                    3.1 g/100 g      --                --
  Energy                          392 kcal/100 g   --                --
  Sodium                          0.441 g/100 g    --                Atomic absorption method
  Arsenicum                       0.5 ppm          --                Atomic absorption method
  Heavy metals                    5 ppm            --                Sodium sulfide method
  Lead                            N.D.             0.05 ppm          Atomic absorption method
  Cadmium                         0.09 ppm         --                Atomic absorption method
  Mercury                         N.D.             0.01 ppm          Reduction vaporization atomic absorption method
  Standard plate count bacteria   Negative         300/g             Standard agar plate culture method
  Coliform bacteria               Negative         1/2.22 g          BGLB method
  Fungus                          Negative         10/g              Potato dextrose agar plate culture method

All analyses were performed at General Foundation Japan Food Research Laboratories (Tokyo, Japan).

Supplementary beverages {#S0002-S20002}
-----------------------

Test beverages were prepared by blending powdered skim milk, citrate, flavors, sweeteners, soybean polysaccharide, food emulsifier, and 200 mg of the fragmented CP1563 powder in water, followed by carbonation, pasteurization, and packaging into 500 mL bottles. The placebo beverage was prepared using the same formula and procedure as for the test beverage, but it did not contain CP1563 powder.

The nutritional contents of the test and placebo beverages are as follows. The test beverage provided a total of 83.7 kJ (20 kcal/day), 1.0 g of protein, 4.5 g of carbohydrates, 0 g of fat, and 128 mg of sodium, whereas the placebo beverage provided a total of 83.7 kJ (20.0 kcal), 1.0 g of protein, 4.5 g of carbohydrates, 0 g of fat, and 128 mg of sodium. The supplementary beverages were obtained from Asahi Soft Drinks Co., Ltd. (Tokyo, Japan).

Subjects {#S0002-S20003}
--------

The subjects were recruited from a pool of volunteers from the Clinical Support Corporation (Sapporo, Japan). The subjects were all healthy adult women and men who underwent a medical examination within a month before the trial at the Medical Corporation Hokubukai Utsukushigaoka Hospital, which is affiliated with the Clinical Support Corporation. The selection criteria included healthy men and women classified as having obesity class I according to the guidelines of the Japanese Society for the Study of Obesity, having a BMI (in kg/m^2^) of 25 or more but less than 30, and not receiving treatment for any lifestyle-related diseases ([@CIT0014]). The exclusion criteria included the following: allergy to cow\'s milk and soy bean; use of medications and health foods affecting lipid metabolism; designation of unsuitable by the medical doctor in charge of the study; a history of severe disorders; a history of gastrointestinal tract surgery; pregnancy or breastfeeding; withdrawal of more than 400 mL of whole blood or blood components within the 4 months prior to the study and/or more than 200 mL of whole blood within the 2 months prior to this study; extremely irregular dietary habits; alternative work schedule or employment in the midnight shift; and smoking and high alcohol intake. Two hundred subjects who fulfilled the eligibility criteria agreed to participate in the study. All subjects were enrolled in the study prior to random allocation. Allocation to the test or placebo group was concealed from the investigator who enrolled the subjects, the nurses, and the medical doctor in charge of the study.

This study was approved by the Institutional Review Board of the Medical Corporation Hokubukai Utsukushigaoka Hospital according to ethical principles and an experimental plan based on the Declaration of Helsinki. Prior to the trial, the medical doctor (KT) provided the subjects with a full explanation of the purpose and methodology of the study. All subjects who agreed to participate in the study provided fully informed consent.

Trial design {#S0002-S20004}
------------

This study followed a randomized, double-blinded, placebo-controlled design, and the experimental periods were divided into 2 weeks of observation before treatment, 12 weeks of treatment, and 4 weeks of observation after treatment. A concealed study coordinator (IT) randomly and blindly assigned the 200 subjects into two groups of 100 that were matched according to age, gender, BMI, and abdominal fat area. Volunteers in one group (*n*=100) received the test beverages (a 500 mL bottle of active beverage per volunteer per day: test group), and those in the other group (*n*=100) received one placebo beverage per day (a 500 mL bottle of the beverage per volunteer per day: placebo group). The subjects were instructed to ingest one bottle daily. The subjects were also instructed to assess their health condition and maintain healthy living practices, including diet and exercise.

The sample size was set to 100 individuals per group to detect changes in the whole body fat area at week 12 of the treatment using a CT scanner between the test and placebo groups at a *p*-value of 0.05, with 80% power using analysis of covariance (ANCOVA) based on information from a preliminary dose-finding study (unpublished information). A dropout rate of 10% was expected; thus, 200 participants were recruited.

Measurements {#S0002-S20005}
------------

At baseline (week 0), every 4 weeks (weeks 4 and 8), at the end of the intervention (week 12), and at the end of the post-observation period (week 16), we performed the following anthropometric measurements at the hospital: body weight, BMI, hip and waist circumferences, body fat percentage, systolic and diastolic blood pressures, pulse rate, body temperature, subcutaneous fat thickness (arm and back), blood sampling, and urinalysis. Abdominal computed tomography (Somatic Emotion 16 Excel, Siemens Japan K.K., Tokyo, Japan) scans and dual bioelectrical impedance analysis (HDS2000, Omron Healthcare Co., Ltd., Kyoto, Japan) were conducted to measure the abdominal visceral and subcutaneous fat areas at weeks 0, 4, 8, 12, and 16 and at weeks 0 and 12, respectively. Height was only measured at the screening examination, and the BMI was calculated based on this measurement.

Each participant maintained a daily record of test or placebo beverage consumption and diet, exercise, and physical condition, including the presence of any subjective symptoms during the trial. The participants also maintained a detailed record of diet and pedometer measurements for 3 consecutive days before each visit: at the start of treatment (week 0) and at weeks 4, 8, 12, and 16. A managerial dietitian analyzed the dietary records to determine the intake of total energy, protein, carbohydrate, fat, total fiber, magnesium, calcium, potassium, and sodium using Excel Eiyokun ver. 6.0 (Kenpakusha Co., Ltd., Tokyo, Japan).

Blood examination and urinalysis were performed at Sapporo Clinical Laboratory Inc. (Sapporo, Japan). The following biochemical and hematological parameters were measured: total protein, albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LD), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (γ-GTP), total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride (TG), uric acid, blood urea nitrogen (BUN), creatinine, sodium, potassium, chloride, calcium, glucose, adiponectin, white blood cells, red blood cells, hemoglobin, hematocrit, and platelets. Protein, glucose, urobilinogen, bilirubin, ketone bodies, occult blood, pH, and density were determined through urinalysis. The participants were required to fast for at least 12 h prior to the test dates.

Medical examinations and inquiries were performed, and a medical doctor (KT) assessed the subjective symptoms at each measurement. All measurements were performed under the supervision of a doctor.

Statistical analysis {#S0002-S20006}
--------------------

Statistical analyses were performed using JMP software (version 11; SAS Institute Japan Ltd., Tokyo, Japan) and SPSS software (version 20; IBM SPSS Japan, Tokyo, Japan). For comparisons between the groups, ANCOVA for repeated measures was primarily used to assess the time course of treatment. Because of the wide ranges of the initial values of these parameters, ANCOVA for repeated measures was the first choice for analyzing the data to not only minimize type II errors but also ensure that the overall probability of type I errors was less than 0.05. Multivariate analysis of variance (MANOVA) for repeated measures was also applied to compare the variation of the mean values with time, where necessary, in cases for which the mean value was considered to be the representative value. ANCOVA with baseline values as the covariate and Student\'s *t*-test were used as *post hoc* tests. *P*\<0.05 for a two-tailed test was considered statistically significant.

Per protocol analysis included only the data from participants who completed the study. Compliance with the test or placebo beverage was assessed, and participants with ≥80% consumption of the beverages were considered eligible.

Results {#S0003}
=======

Approximately 21 kg of dried CP1563 cells were harvested from the culture medium of 4,000 L. The fragmentation process was successfully completed as indicated by an average long dimension of less than 70% of that of the native bacteria ([@CIT0009]). The results of a standard method analysis of the fragmented bacterial preparation are shown in [Table 2](#T0002){ref-type="table"}. The quality was satisfactory for a food material for the test beverages.

In total, 200 subjects were enrolled, and 197 participants completed the present study. These individuals were randomly assigned to fragmented CP1563 or control treatments. The progress through the phases of the trial is shown in [Fig. 1](#F0001){ref-type="fig"}. Three individuals discontinued participation in the study because of an inability to comply with the time constraint (*n*=1) or an extended business trip (*n*=2). During the study, adverse effects, such as abnormal values of hepatic or renal function, cutaneous symptoms, nausea, abdominal discomfort, and edema caused by PPARα or PPARγ synthetic agonists, were not observed in the test group. Although transient diarrhea (four subjects in the placebo group and two subjects in the test group) and constipation (two subjects in the placebo group and one subject in the test group) were observed, the doctor determined that the symptoms were not associated with the intake of the supplementary beverages. No signs of imbalance in the occurrence rates of unwellness between the test and placebo groups were recorded.

![Flow diagram of the trial.](MEHD-27-30312-g001){#F0001}

The characteristics of the subjects at baseline are shown in [Table 3](#T0003){ref-type="table"}. No significant differences were observed between the test and placebo groups regarding gender, age, BMI, or abdominal fat area (*p*\>0.05). This study achieved relatively high compliance: the frequencies of test or placebo beverage consumption were 99.85±0.59 and 99.84±0.59, respectively.

###### 

Baseline characteristics of the participants[a](#TF0001){ref-type="table-fn"}

                                           Placebo group   CP1563 group
  -------------------------- ------------- --------------- --------------
  Male                                     50              50
  Female                                   50              50
  Age                        \(y\)         46.6±11.9       46.2±12.0
  Body weight                (kg)          76.4±9.5        76.7±9.6
  Height                     \(cm\)        163.6±9.3       164.3±9.4
  Body mass index            (kg/m^2^)     28.3±1.6        28.5±1.6
  Waist circumference        \(cm\)        97.6±4.8        98.0±4.8
  Hip circumference          \(cm\)        100.4±4.0       101.5±4.1
  Visceral fat area          (cm^2^)       109.4±35.6      106.9±35.9
  Subcutaneous fat area      (cm^2^)       277.5±63.0      285.9±63.6
  Whole body fat area        (cm^2^)       386.8±59.1      392.8±59.8
  Systolic blood pressure    (mm Hg)       124.4±17.7      125.5±17.9
  Diastolic blood pressure   (mm Hg)       73.6±13.2       75.0±13.3
  Pulse rate                 (beats/min)   69.3±9.8        69.6±9.9

×±SD.

No significant difference was observed between groups.

BMI, body fat percentage, abdominal fat area, and whole body fat area {#S0003-S20001}
---------------------------------------------------------------------

The baseline demographic, anthropometric, and clinical characteristics of the participants were comparable in both groups ([Table 3](#T0003){ref-type="table"}). Significant differences were not observed between the two groups. Daily records indicated that the daily physical activity was constant during the study period. [Table 4](#T0004){ref-type="table"} shows the daily energy, protein, fat, and carbohydrate intake based on body weight. No significant changes were observed in either group.

###### 

Daily energy, protein, fat, and carbohydrate intake based on weight measured every 4 weeks[a](#TF0002){ref-type="table-fn"}

                                             Treatment period                             
  -------------------------------- --------- ------------------ ------------ ------------ ------------
  Energy intake (kJ/day/kg)        Placebo   332.6±72.8         320.9±72.4   297.5±71.9   321.3±72.8
                                   CP1563    306.3±73.6         315.5±73.2   319.2±72.8   297.1±73.6
  Protein intake (g/day/kg)        Placebo   3.0±0.9            2.8±0.8      2.5±0.7      2.8±0.8
                                   CP1563    2.8±0.9            2.7±0.8      2.8±0.7      2.6±0.8
  Fat intake (g/day/kg)            Placebo   2.6±0.8            2.6±0.9      2.4±0.8      2.6±0.9
                                   CP1563    2.3±0.8            2.6±0.9      2.6±0.8      2.4±0.9
  Carbohydrate intake (g/day/kg)   Placebo   10.5±2.6           10.0±2.4     9.3±2.6      9.9±2.5
                                   CP1563    9.9±2.6            9.8±2.4      10.0±2.5     9.5±2.6

×± SD.

No significant difference was observed between groups (MANOVA was used for repeated measures analysis).

Time-dependent changes in BMI, body fat percentage, visceral fat area, and whole body fat area are shown in [Fig. 2](#F0002){ref-type="fig"} (*p*=0.524, *p*\<0.001, *p*\<0.001, and *p*\<0.001, respectively). In stratified analyses, the subjects whose visceral fat exceeded 100 cm^2^ showed a significantly larger reduction in the test group than in the placebo group in whole body fat area (*p*\<0.001, data not shown). However, the participants in the other subgroup with a low baseline value (visceral fat\<100 cm^2^) also showed a significant reduction in the body fat area in the test group (*p*\<0.05 \[test for efficacy ratio\], *p*=0.031; 390.19±4.75 cm^2^ at the start \[mean±SEM\] to 381.89±4.70 cm^2^ at 12 weeks on CP1563 \[mean±SEM\]), but those in the placebo group did not. Another stratified analysis of the participants in the subgroup with a high baseline value (visceral fat ≥100 cm^2^) exhibited a larger reduction in visceral fat area ([Fig. 3](#F0003){ref-type="fig"}; *p*\<0.001). Regarding body weight, a significant difference was observed between the placebo and test groups in men ([Table 5](#T0005){ref-type="table"}; *p*=0.035). In women, a reduction in the body weight was observed in the test group ([Table 5](#T0005){ref-type="table"}; *p*=0.051). Regarding waist circumference, a significant interaction between the factor group and time was observed (*p*\<0.001), and the graph showed a significant difference between the placebo and test groups at 12 weeks in the measurement item, as shown in [Fig. 4](#F0004){ref-type="fig"}a. Similarly, in terms of hip circumference, a significant difference between the placebo and test groups was noted ([Fig. 4](#F0004){ref-type="fig"}b; *p*=0.015).

![Changes in anthropometric measurements. (a) BMI, (b) body fat percentage, (c) visceral fat area, and (d) whole body fat area. Changes in BMI and fat area based on CT scans from baseline in obese class I participants during the 12-week period of consumption in the test group (closed circles; *n*=100) and the placebo group (open circles; *n*=100). The participants ingested one bottle (500 mL) of carbonated beverage containing fragmented CP1563 or the same amount of carbonated placebo beverage daily for 12 weeks. After the treatment was initiated, the whole and visceral fat areas were measured at weeks 4, 8, 12 and 16. Subgroup analysis was performed after the groups were divided into two subgroups using 100 cm^2^ of visceral fat area as the cutoff value. The data are presented as the means±SEM. Statistical significance was determined according to the interaction of the factor group×time using ANCOVA for repeated measures.](MEHD-27-30312-g002){#F0002}

![Time-dependent changes in visceral fat area (cm^2^) in subjects with higher values (≥100 cm^2^) at baseline. Visceral fat areas were measured at weeks 4, 8, 12 and 16 in subjects with higher initial values at baseline. The solid line is the regression line, and the dotted line shows the 95% confidence intervals of the population mean values. Statistical significance was determined according to the interaction of the factor group×time using ANCOVA for repeated measures.](MEHD-27-30312-g003){#F0003}

![Changes in (a) waist, and (b) hip circumferences at week 12. Statistical significance was determined according to the interaction of the factor group×time using ANCOVA.](MEHD-27-30312-g004){#F0004}

###### 

Changes in anthropometric measurements during the course of the study

                                                  Factor            Probability   Regression
  --------------------------------- ------------- ----------------- ------------- ---------------------------------------------
  Body weight (kg)                  Whole model   Group             *p*=0.505     CP1563: δBW=0.496−0.006×Init. BW
                                                  Group×Init. BW    *p*=0.202     Placebo: δBW=0.950−0.010×Init. BW
                                    Female        Group             *p*=0.051     CP1563: δBW=1.591−0.021×Init. BW
                                                  Group×Init. BW    *p*=0.059     Placebo: δBW=−0.551+0.012×Init. BW
                                    Male          Group             *p*=0.035     CP1563: δBW=−1.284+0.153×Init. BW
                                                  Group×Init. BW    *p*=0.104     Placebo: δBW=2.414−0.027×Init. BW
  BMI (kg/m^2^)                     Whole model   Group             *p*=0.524     CP1563: δBMI=0.025−3.550×10^--5^× Init. BMI
                                                  Group×Init. BMI   *p*=0.757     Placebo: δBMI=0.368−0.010×Init. BMI
                                    Female        Group             *p*=0.111     CP1563: δBMI=0.737−0.024×Init. BMI
                                                  Group×Init. BMI   *p*=0.195     Placebo: δBMI=−0.280+0.014×Init. BMI
                                    Male          Group             *p*=0.026     CP1563: δBMI=−1.076+0.038×Init. BMI
                                                  Group×Init. BMI   *p*=0.094     Placebo: δBMI=0.942−0.031×Init. BMI
  Body fat percentage (%)           Whole model   Group             *p*\<0.001    CP1563: δBFP=−0.882+0.024×Init. BFP
                                                  Group×Init. BFP   *p*\<0.001    Placebo: δBFP=1.167−0.029×Init. BFP
                                    Female        Group             *p*=0.911     CP1563: δBFP=1.517−0.034×Init. BFP
                                                  Group×Init. BFP   *p*=0.547     Placebo: δBFP=1.251−0.029×Init. BFP
                                    Male          Group             *p*\<0.001    CP1563: δBFP=0.247−0.018×Init. BFP
                                                  Group×Init. BFP   *p*\<0.001    Placebo: δBFP=7.829−0.269×Init. BFP
  Waist circumference (cm)          Whole model   Group             *p*=0.233     CP1563: δWC=2.413−0.024×Init. WC
                                                  Group×Init. WC    *p*\<0.001    Placebo: δWC=1.228−0.012×Init. WC
                                    Female        Group             *p*=0.010     CP1563: δWC=3.330−0.032×Init. WC
                                                  Group×Init. WC    *p*=0.003     Placebo: δWC=−0.812+0.011×Init. WC
                                    Male          Group             *p*=0.082     CP1563: δWC=−0.072+4.382×10^--6^×Init. WC
                                                  Group×Init. WC    *p*=0.039     Placebo: δWC=1.840−0.020×Init. WC
  Hip circumference (cm)            Whole model   Group             *p*=0.089     CP1563: δHC=2.173−0.022×Init. HC
                                                  Group×Init. HC    *p*=0.015     Placebo: δHC=0.329−0.004×Init. HC
                                    Female        Group             *p*=0.338     CP1563: δHC=3.114−0.0301×Init. HC
                                                  Group×Init. HC    *p*=0.063     Placebo: δHC=1.130−0.012×Init. HC
                                    Male          Group             *p*=0.077     CP1563: δHC=1.269−0.013×Init. HC
                                                  Group×Init. HC    *p*=0.123     Placebo: δHC=−0.265+0.002×Init. HC
  Visceral fat area (cm^2^)         Whole model   Group             *p*=0.637     CP1563: δVF=3.443−0.041×Init. VF
                                                  Group×Init. VF    *p*\<0.001    Placebo: δVF=4.682−0.062×Init. VF
                                    Female        Group             *p*=0.575     CP1563: δVF=4.182+0.602×Init. VF
                                                  Group×Init. VF    *p*\<0.001    Placebo: δVF=6.045−0.083×Init. VF
                                    Male          Group             *p*=0.935     CP1563: δVF=5.321−0.049×Init. VF
                                                  Group×Init. VF    *p*=0.014     Placebo: δVF=4.946−0.058×Init. VF
  Subcutaneous fat area (cm^2^)     Whole model   Group             *p*=0.078     CP1563: δSCF=−4.385+0.011×Init. SCF
                                                  Group×Init. SCF   *p*=0.343     Placebo: δSCF=2.503−0.009×Init. SCF
                                    Female        Group             *p*=0.368     CP1563: δSCF=−3.432−0.006×Init. SCF
                                                  Group×Init. SCF   *p*=0.823     Placebo: δSCF=2.968−0.008×Init. SCF
                                    Male          Group             *p*=0.022     CP1563: δSCF=−6.776+0.022×Init. SCF
                                                  Group×Init. SCF   *p*=0.088     Placebo: δSCF=5.296−0.023×Init. SCF
  Whole body fat area (cm^2^)       Whole model   Group             *p*=0.013     CP1563: δWBF=1.812−0.012×Init. WBF
                                                  Group×Init. WBF   *p*\<0.001    Placebo: δWBF=21.74−0.059×Init. WBF
                                    Female        Group             *p*=0.192     CP1563: δWBF=9.647−0.031×Init. WBF
                                                  Group×Init. WBF   *p*=0.003     Placebo: δWBF=24.333−0.063×Init. WBF
                                    Male          Group             *p*=0.009     CP1563: δWBF=--11.707+0.025×Init. WBF
                                                  Group×Init. WBF   *p*=0.008     Placebo: δWBF=21.625−0.061×Init. WBF
  Systolic blood pressure (mmHg)    Whole model   Group             *p*=0.291     CP1563: δSBP=1.338−0.012×Init. SBP
                                                  Group×Init. SBP   *p*=0.176     Placebo: δSBP=2.614−0.019×Init. SBP
                                    Female        Group             *p*=0.319     CP1563: δSBP=0.443−0.004×Init. SBP
                                                  Group×Init. SBP   *p*=0.613     Placebo: δSBP=2.202−0.017×Init. SBP
                                    Male          Group             *p*=0.634     CP1563: δSBP=2.220−0.020×Init. SBP
                                                  Group×Init. SBP   *p*=0.218     Placebo: δSBP=3.013−0.022×Init. SBP
  Diastolic blood pressure (mmHg)   Whole model   Group             *p*=0.432     CP1563: δDBP=9.562−0.122×Init. DBP
                                                  Group×Init. DBP   *p*\<0.001    Placebo: δDBP=11.657−0.138×Init. DBP
                                    Female        Group             *p*=0.016     CP1563: δDBP=7.552−0.104×Init. DBP
                                                  Group×Init. DBP   *p*\<0.001    Placebo: δDBP=17.0818−0.205×Init. DBP
                                    Male          Group             *p*=0.173     CP1563: δDBP=12.015−0.147×Init. DBP
                                                  Group×Init. DBP   *p*\<0.001    Placebo: δDBP=7.1040.083×Init. DBP

BMI, body mass index; ANCOVA for repeated measures was used to analyze the changes in these measures during the course of the study.

Systolic blood pressure did not show a significant change; however, diastolic blood pressure was affected by the constant ingestion of fragmented CP1563 ([Table 5](#T0005){ref-type="table"}; *p*\<0.001).

Parameters relevant to lipid, glucose, and liver metabolism {#S0003-S20002}
-----------------------------------------------------------

Changes in lipid and glucose metabolism are shown in [Table 6](#T0006){ref-type="table"}. The regular intake of fragmented CP1563 significantly affected the triglyceride and total and LDL-cholesterol levels in the plasma samples ([Fig. 5](#F0005){ref-type="fig"}; *p*\<0.001, *p*\<0.001, and *p*\<0.001, respectively). Larger reductions of these lipid compositions were observed in the test group than in the placebo group at week 12, particularly in men ([Table 6](#T0006){ref-type="table"}). There was no major change in the HDL-cholesterol level, but a significant difference between the placebo and test groups was observed, particularly in men.

![Changes in biological markers in the blood after 12 weeks of ingestion: triglycerides, total cholesterol, and LDL-cholesterol. Statistical significance was determined according to the interaction of the factor group×time using ANCOVA for repeated measures.](MEHD-27-30312-g005){#F0005}

###### 

Changes in serum metabolic variables during the course of the study

                                            Factor                Probability   Regression
  --------------------------- ------------- --------------------- ------------- ------------------------------------------
  Total cholesterol (mg/dL)   Whole model   Group                 *p*=0.063     CP1563: δT-C=30.0878−0.132×Init. T-C
                                            Group×Init. T-C       *p*\<0.001    Placebo: δT-C=14.012−0.068×Init. T-C
                              Female        Group                 *p*=0.884     CP1563: δT-C=19.889−0.084×Init. T-C
                                            Group×Init. T-C       *p*=0.006     Placebo: δT-C=18.237−0.079×Init. T-C
                              Male          Group                 *p*=0.029     CP1563: δT-C=43.043−0.192×Init. T-C
                                            Group×Init. T-C       *p*\<0.001    Placebo: δT-C=13.360−0.073×Init. T-C
  HDL-cholesterol (mg/dL)     Whole model   Group                 *p*=0.574     CP1563: δHDL-C=3.462−0.054×Init. HDL-C
                                            Group×Init. HDL-C     *p*=0.004     Placebo: δHDL-C=2.498−0.042×Init. HDL-C
                              Female        Group                 *p*=0.631     CP1563: δHDL-C=3.527−0.055×Init. HDL-C
                                            Group×Init. HDL-C     *p*=0.244     Placebo: δHDL-C=2.016−0.016×Init. HDL-C
                              Male          Group                 *p*=0.413     CP1563: δHDL-C=3.439−0.054×Init. HDL-C
                                            Group×Init. HDL-C     *p*\<0.001    Placebo: δHDL-C=5.118−0.112×Init. HDL-C
  LDL-cholesterol (mg/dL)     Whole model   Group                 *p*=0.014     CP1563: δLDL-C=23.956−0.170×Init. LDL-C
                                            Group×Init. LDL-C     *p*\<0.001    Placebo: δLDL-C=10.863−0.083×Init. LDL-C
                              Female        Group                 *p*=0.299     CP1563: δLDL-C=19.785−0.141×Init. LDL-C
                                            Group×Init. LDL-C     *p*\<0.001    Placebo: δLDL-C=12.117−0.089×Init. LDL-C
                              Male          Group                 *p*=0.019     CP1563: δLDL-C=28.728−0.202×Init. LDL-C
                                            Group×Init. LDL-C     *p*\<0.001    Placebo: δLDL-C=8.559−0.080×Init. LDL-C
  Triglyceride (mg/dL)        Whole model   Group                 *p*=0.950     CP1563: δTG=21.142−0.176×Init. TG
                                            Group×Init. TG        *p*\<0.001    Placebo: δTG=20.767−0.168×Init. TG
                              Female        Group                 *p*=0.216     CP1563: δTG=37.363−0.144×Init. TG
                                            Group×Init. TG        *p*\<0.001    Placebo: δTG=27.526−0.267×Init. TG
                              Male          Group                 *p*=0.604     CP1563: δTG=23.7438−0.194×Init. TG
                                            Group×Init. TG        *p*\<0.001    Placebo: δTG=18.927−0.118×Init. TG
  Fasting glucose (mg/dL)     Whole model   Group                 *p*\<0.001    CP1563: δGLC=15.101−0.161×Init. GLC
                                            Group×Init. GLC       *p*\<0.001    Placebo: δGLC=−5.624+0.071×Init. GLC
                              Female        Group                 *p*=0.001     CP1563: δGLC=23.229−0.250×Init. GLC
                                            Group×Init. GLC       *p*\<0.001    Placebo: δGLC=6.949−0.086×Init. GLC
                              Male          Group                 *p*=0.004     CP1563: δGLC=2.886−0.024×Init. GLC
                                            Group×Init. GLC       *p*\<0.001    Placebo: δGLC=−13.855+0.179×Init. GLC
  Fasting insulin (mU/mL)     Whole model   Group                 *p*=0.418     Incomputable
                                            Group×Init. Ins.      *p*=0.004     
  HOMA-IR                     Whole model   Group                 *p*=0.598     Incomputable
                                            Group×Init. HOMA-IR   *p*\<0.001    
  Uric acid (mg/dL)           Whole model   Group                 *p*=0.022     CP1563: δUA=0.822−0.144×Init. UA
                                            Group×Init. UA        *p*\<0.001    Placebo: δUA=0.436+0.087×Init. UA
                              Female        Group                 *p*=0.029     CP1563: δUA=0.603−0.104×Init. UA
                                            Group×Init. UA        *p*=0.005     Placebo: δUA=0.067+0.020×Init. UA
                              Male          Group                 *p*=0.870     CP1563: δUA=1.070−0.180×Init. UA
                                            Group×Init. UA        *p*\<0.001    Placebo: δUA=1.019+0.169×Init. UA

T-C, total cholesterol; Init., initial; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; TG, triglyceride; GLC, glucose; Ins, insulin; HOMA-IR, homeostasis model assessment-insulin resistance; UA, uric acid.

Statistical analysis with ANCOVA was used for repeated measures, except for the items 'fasting insulin' and 'HOMA-IR'.

The fasting insulin concentration was measured at only 2 time points: before and after ingestion; therefore, ANCOVA was used for these variables.

Blood glucose, insulin, and homeostasis model assessment-insulin resistance (HOMA-IR) were affected by the ingestion of fragmented CP1563 ([Fig. 6](#F0006){ref-type="fig"}, [Table 6](#T0006){ref-type="table"}), and significant differences between the placebo and test groups were observed in these parameters (*p*\<0.001, *p*=0.004, and *p*\<0.001, respectively). However, glycosylated hemoglobin (HbA1c) levels were not significantly different between the two groups (data not shown). Total bilirubin was significantly decreased in the test group during the early stage of the time course, especially in women ([Table 7](#T0007){ref-type="table"}; *p*\<0.001). Uric acid was also significantly reduced in the test group ([Fig. 6](#F0006){ref-type="fig"}; *p*\<0.001). These differences were relatively well shown in the participants who had high baseline values for these parameters.

![Changes in the concentrations of chemical substance in the blood after 12 weeks of ingestion: glucose, insulin, bilirubin and uric acid. The solid line is the regression line, and the dotted line shows the 95% confidence intervals of the population mean values. Statistical significance was determined according to the interaction of the factor group×time using ANCOVA for repeated measures.](MEHD-27-30312-g006){#F0006}

###### 

Changes in hematological and serum biochemical variables during the course of the study

  Factor                  Probability         Regression   
  ----------------------- ------------------- ------------ -----------------------------------------
  WBC (×1000/µL)          Group               *p*=0.017    CP1563: δWBC=0.528−0.073×Init. WBC
                          Group×Init. WBC     *p*\<0.001   Placebo: δWBC=1.163−0.162×Init. WBC
  RBC (×10,000/µL)        Group               *p*=0.249    CP1563: δRBC=43.179−0.088×Init. RBC
                          Group×Init. RBC     *p*\<0.001   Placebo: δRBC=29.004−0.062×Init. RBC
  Hemoglobin (g/dL)       Group               *p*=0.155    CP1563: δHb=1.005−0.070×Init. Hb
                          Group×Init. Hb      *p*\<0.001   Placebo: δHb=0.513−0.041×Init. Hb
  Hematocrit (%)          Group               *p*=0.106    CP1563: δHt=3.441−0.079×Init. Ht
                          Group×Init. Ht      *p*\<0.001   Placebo: δHt=1.488−0.039×Init. Ht
  Platelet (×10,000/µL)   Group               *p*=0.441    CP1563: δPLT=2.006−0.571×Init. PLT
                          Group×Init. PLT     *p*=0.001    Placebo: δPLT=2.006−0.055×Init. PLT
  ALT (IU/L)              Group               *p*=0.003    CP1563: δALT=5.373−0.181×Init. ALT
                          Group×Init. ALT     *p*\<0.001   Placebo: δALT=1.105−0.039×Init. ALT
  AST (IU/L)              Group               *p*\<0.001   CP1563: δAST=5.666−0.149×Init. AST
                          Group×Init. AST     *p*\<0.001   Placebo: δAST=--2.302+0.193×Init. AST
  γ-GTP (IU/L)            Group               *p*=0.005    CP1563: δγGTP=−2.351+0.080×Init. γGTP
                          Group×Init. γ-GTP   *p*\<0.001   Placebo: δγGTP=4.093−0.128×Init. γGTP
  LD (IU/L)               Group               *p*\<0.001   CP1563: δLD=74.931−0.388×Init. LD
                          Group×Init. LD      *p*\<0.001   Placebo: δLD=25.641−0.138×Init. LD
  TP (g/dL)               Group               *p*=0.011    CP1563: δTP=2.241−0.305×Init. TP
                          Group×Init. TP      *p*\<0.001   Placebo: δTP=1.316−0.183×Init. TP
  BUN (mg/dL)             Group               *p*=0.030    CP1563: δBUN=1.710−0.127×Init. BUN
                          Group×Init. BUN     *p*\<0.001   Placebo: δBUN=3.404−0.262×Init. BUN
  Uric acid (mg/dL)       Group               *p*=0.022    CP1563: δUA=0.822−0.144×Init.UA
                          Group×Init. UA      *p*\<0.001   Placebo: δUA=0.436+0.087×Init.UA
  Creatinine (mg/dL)      Group               *p*=0.428    CP1563: δCRE=0.046−0.062×Init. CRE
                          Group×Init. CRE     *p*\<0.001   Placebo: δCRE=0.033−0.040×Init. CRE
  Bilirubin (mg/dL)       Group               *p*=0.426    CP1563: δT-Bil=0.161−0.266×Init. T-Bil
                          Group×Init. T-Bil   *p*\<0.001   Placebo: δT-Bil=0.137−0.223×Init. T-Bil
  Sodium (mEq/L)          Group               *p*=0.283    CP1563: δNa=46.984−0.330×Init. Na
                          Group×Init. Na      *p*\<0.001   Placebo: δNa=55.558−0.391×Init. Na
  Potassium (mEq/L)       Group               *p*=0.351    CP1563: δK=1.486−0.368×Init. K
                          Group×Init. K       *p*\<0.001   Placebo: δK=1.297−0.321×Init. K
  Chloride (mEq/L)        Group               *p*=0.048    CP1563: δCL=26.277−0.257×Init. Cl
                          Group×Init. Cl      *p*\<0.001   Placebo: δCL=37.498−0.366×Init. Cl

WBC, white blood cell; RBC, red blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GTP, γ-glutamyl transpeptidase; LD, lactate dehydrogenase; TP, total protein; BUN, blood urea nitrogen; UA, uric acid; CRE, creatinine; T-Bil, total bilirubin; Na, sodium; K, potassium; Cl, chloride.

Statistical significance was evaluated using ANCOVA for repeated measures.

Blood test valuables and urinalysis {#S0003-S20003}
-----------------------------------

BUN, sodium, and chloride exhibited significant reductions in the test group compared with the placebo group ([Table 7](#T0007){ref-type="table"}, [Fig. 7](#F0007){ref-type="fig"}a and b; *p*\<0.001, *p*\<0.001, and *p*\<0.001, respectively). In contrast, potassium was increased in the test group ([Fig. 7](#F0007){ref-type="fig"}c; *p*\<0.001). Red blood cells, hemoglobin, and hematocrit showed significant increases in the test group compared with the placebo group ([Table 7](#T0007){ref-type="table"} and [Fig. 8](#F0008){ref-type="fig"}; *p*\<0.001, *p*\<0.001, and *p*\<0.001, respectively). In contrast, the white blood cell count was significantly lower in the test group than in placebo group ([Table 7](#T0007){ref-type="table"}; *p*\<0.001). ALT, AST, and LD exhibited significant reductions in the test group compared with those in the placebo group ([Table 7](#T0007){ref-type="table"}; *p*\<0.001, *p*\<0.001, and *p*\<0.001, respectively). In contrast, γ-GTP was increased to a greater extent in the test group than in the placebo group ([Table 7](#T0007){ref-type="table"}; *p*\<0.001). These changes in blood test values were, however, within the normal ranges, and even the results obtained for individual subjects failed to reveal changes that might develop into abnormal ranges (data not shown).

![Changes in the plasma concentrations of chemical elements throughout the ingestion period: (a) sodium, (b) chloride and (c) potassium. Closed circles indicate the test group, and open circles indicate the placebo group. Statistical significance was determined according to the interaction of the factor group×time using ANCOVA for repeated measures.](MEHD-27-30312-g007){#F0007}

![Changes in red blood cell counts throughout the ingestion period: (a) erythrocyte, (b) hemoglobin concentration and (c) hematocrit concentration. Closed circles indicate the test group, and open circles indicate the placebo group. Statistical significance was determined according to the interaction of the factor group×time using ANCOVA for repeated measures.](MEHD-27-30312-g008){#F0008}

After CP1563 treatment, decreases in the number of white blood cells (WBCs) and the concentrations of AST, ALT, LD, BUN, uric acid, creatinine, sodium, and chloride; and increases in γ-GTP and potassium were observed ([Table 7](#T0007){ref-type="table"}). However, these changes were within the normal ranges. In addition, no statistically significant changes in any of the other markers, except those mentioned above, were recorded. No abnormal changes were observed in urinalysis during or after intervention in the test and placebo groups (data not shown). Although two subjects were positive for uric protein and uric glucose during the pre-intake period, no abnormal changes were observed between the intake and post-intake periods.

Discussion {#S0004}
==========

In the present study, we demonstrated that non-viable, that is, paraprobiotic, lactic acid bacteria consumption has a beneficial body fat-lowering effect on humans and affects lipid, glucose, and uric acid metabolism. Regarding the relationship between fat metabolism and the administration of lactic acid-producing bacteria, the effects of *Bifidobacterium breve* B-3 ([@CIT0015]), *Lactobacillus gasseri* SBT2055 ([@CIT0016]), and other bacteria on abdominal adiposity have been determined in clinical trials. Our previous study has evaluated the PPARα/γ activation potential of organic extracts from various lactic acid bacteria *in vitro*, and the highest activity was observed in *L. amylovorus* CP1563 ([@CIT0009]). Furthermore, the anti-dyslipidemic and anti-obesity effects of fragmented CP1563 have been recorded in high-fat diet-induced obese mice, and the fragmentation of CP1563 is required for its PPARα-agonistic activity *in vivo*. In the present study, we demonstrated the effect of 12 weeks of ingestion of fragmented CP1563 on lipid metabolism, including decreased body fat, plasma triglycerides, and LDL-cholesterol in pre-obese and mildly obese participants. All 200 participants were confirmed to meet the criteria for investigating food for specified health use (FOSHU) for somatic fat reduction, as verified by the control doctor (KT). Significant reductions in plasma glucose, insulin, HOMA-IR, and uric acid were observed in the test groups ([Fig. 6](#F0006){ref-type="fig"} and [Table 6](#T0006){ref-type="table"}). The parameters used to diagnose metabolic syndrome included waist circumstance, which represents visceral fat area; insulin resistance; serum/plasma triglycerides and HDL-cholesterol; blood pressure; and fasting blood glucose. In the present study, the body fat and visceral fat areas; insulin resistance; and levels of plasma triglycerides, HDL-cholesterol, insulin, HOMA-IR, and fasting blood glucose were significantly improved in the test group compared with the placebo group ([Tables 5](#T0005){ref-type="table"} and [6](#T0006){ref-type="table"}). The results also demonstrated that a longer ingestion period is desirable to obtain health-promoting benefits. The expected changes only begin to occur during ingestion periods of at least 3 months. Regarding the average initial visceral fat area, the initial value obtained in the present study was lower than those in other studies with similar study designs: 108.1±35.8 (cm^2^) in the present study compared with 114--118 (cm^2^) in other studies ([@CIT0016], [@CIT0017]). In addition, the initial range of visceral fat area values of the participants was wider than previously reported in other studies. The initial value of the visceral fat area was inversely correlated with the reduction in visceral fat area after 12 weeks of intervention in the test group compared with the placebo group ([Fig. 3](#F0003){ref-type="fig"}), suggesting that a reduction in visceral fat area is expected when the initial value falls within a higher range. However, the whole body fat area in the participants with low visceral fat (\<100 cm^2^) was also significantly reduced in the test group but not in the same subgroup of the placebo group. This fact may suggest that fragmented CP1563 cells work not only in the patients classified as obese class I but also in individuals with moderate levels of fat. These results suggest that the constant intake of beverages containing fragmented CP1563 could improve metabolic syndrome, although further clinical studies are needed to determine the effects of longer ingestion periods.

These findings indicate that fragmented *L. amylovorus* CP1563 has the same benefits as synthetic PPARα, PPARγ, or PPARα/γ agonists. Furthermore, uric acid was significantly decreased in the test group compared with the placebo group ([Fig. 6](#F0006){ref-type="fig"}). The synthetic PPARα agonist, fenofibrate, was shown to significantly decrease the concentration of serum uric acid in healthy male subjects ([@CIT0018]). The PPARα agonist property of fragmented CP1563 likely decreased the plasma uric acid levels in the present study. The serum level of uric acid is positively correlated with the frequency of metabolic syndrome, and metabolic syndrome is associated with a high incidence of hyperuricemia ([@CIT0019]). However, the synthetic agonists exhibit some adverse effects. Indeed, the use of glitazones leads to weight gain, edema, bone fractures, and heart failure, which limits the use of these drugs in diabetic patients with high lipid levels ([@CIT0010]). In the present study, no adverse effects attributed to the administration of the fragmented CP1563 were observed (data not shown). Food-derived PPAR agonists, such as fragmented CP1563, are expected to be relatively safe compared with PPAR agonist drugs; and dietary approaches utilizing food ingredients with PPARα and PPARγ dual-activating properties have become important for preventing metabolic disorders.

In addition, the average reduction in visceral fat after intervention in the present study was relatively small compared with those observed in previous studies ([@CIT0016], [@CIT0017]). One limitation of this study is the seasonal variation in fat metabolism. The test beverages were consumed from September to December (autumn to winter), a period when people tend to gain weight easily. It has been reported that body weight tends to decrease in summer and increase in winter ([@CIT0020], [@CIT0021]); therefore, in the present study, the visceral fat in the test group was relatively unlikely to decrease ([Fig. 2](#F0002){ref-type="fig"}c). Another limitation is the lack of information concerning the daily food consumption and calorie intake. We did not ensure strict dietary regulations or supply the participants with study diets in the present study; instead, the participants maintained a detailed record of diet and pedometer measurements for 3 consecutive days prior to each visit. Analysis of the records revealed that the calorie intake and nutrient composition were similar between the placebo and test groups ([Table 4](#T0004){ref-type="table"}). However, other detailed information concerning daily dietary records was absent, and the daily calorie intake and nutrition might be altered during the intervention period, although the participants were instructed to maintain healthy living habits, including diet and exercise. Furthermore, to some extent, 'misreporting' might have occurred. Indeed, approximately one-fifth of all study participants have been shown to engage in 'underreporting', whereas half of the study participants have been shown to demonstrate 'over reporting', which is a common phenomenon in the assessment of habitual dietary intake ([@CIT0022], [@CIT0023]).

The results of the present study suggest that fragmented CP1563 is a novel foodstuff that regulates lipid and glucose metabolism. Several food-derived natural compounds with PPARα and/or PPARγ dual-activating properties have been reported ([@CIT0024]). For example, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are PPARα agonists, and they are representative of foods that affect lipid metabolism, as supported by abundant evidence from clinical studies ([@CIT0025]). The dosages used in relevant studies range from 0.185 to 9 g/day and are much higher than the dosage of fragmented CP1563 used in the present study, suggesting that lower dosages of CP1563 could exhibit PPAR agonist activity equivalent to the DHA/EPA activity. Alternatively, PPARα and PPARγ dual activation could be the reason underlying the lower effective dosage of fragmented CP1563 ([@CIT0009]). We isolated PPARα/γ agonists from CP1563 to clarify the significance of the ligands' roles in metabolism. The exact working mechanisms of the fragmented CP1563 are now under investigation. The series of information of the working materials, their working mechanisms, their absorbency indices, and their structures will soon be published.

In lipid metabolism, a close relationship between the composition of gut microbiota and obesity might exist, although conflicting research findings have been reported ([@CIT0026]). In the present study, we did not investigate changes in the gut microbiota during the intervention period according to CP1563 treatment, although much attention has been paid to gut microbes. If changes in gut microbiota are related to obesity, then non-viable fragmented CP1563 might affect the composition. Indeed, in the case of *L. gasseri* CP2305, the consumption of beverages containing this strain led to some changes in the gut microbiota ([@CIT0027], [@CIT0028]). Thus, an undefined component(s) of CP1563 might directly or indirectly influence the composition of the gut microbiota and subsequently improve glucose and fat metabolism. This possibility remains to be investigated.

In conclusion, the daily consumption of beverages containing fragmented CP1563 for 12 weeks by obese class I subjects improves anthropometric measurements and markers related to lipid and glucose metabolism without any adverse effects. Although further clinical trials and investigations of the mechanisms of action are needed, the results of the present study suggest that the consumption of foods containing fragmented CP1563 ameliorates obesity and prevents metabolic syndrome and complications.
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